Barclays
ZYNE

Barclays’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Barclays’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,268
Closed -$31K – 4866
2021
Q3 		$31K Sell
7,268
-1,943
-21% -$8.67K ﹤0.01% 4262
2021
Q2 		$49K Buy
9,211
+8,472
+1,146% +$40.7K ﹤0.01% 4144
2021
Q1 		$3K Buy
739
+734
+14,680% +$3.33K ﹤0.01% 4541
2020
Q4 		$0 Sell
5
-4,500
-100% -$17.1K ﹤0.01% 5220
2020
Q3 		$15K Sell
4,505
-6,552
-59% -$24.1K ﹤0.01% 4947
2020
Q2 		$37K Sell
11,057
-1,186
-10% -$5.61K ﹤0.01% 5046
2020
Q1 		$46K Sell
12,243
-10,988
-47% -$51K ﹤0.01% 5281
2019
Q4 		$140K Buy
23,231
+5,685
+32% +$38.9K ﹤0.01% 5279
2019
Q3 		$131K Sell
17,546
-46,654
-73% -$526K ﹤0.01% 5277
2019
Q2 		$870K Buy
64,200
+58,502
+1,027% +$675K ﹤0.01% 3831
2019
Q1 		$31K Sell
5,698
-26,732
-82% -$130K ﹤0.01% 6165
2018
Q4 		$96K Buy
32,430
+15,758
+95% +$86.3K ﹤0.01% 5070
2018
Q3 		$136K Buy
16,672
+1,272
+8% +$9.76K ﹤0.01% 5304
2018
Q2 		$150K Sell
15,400
-1,094
-7% -$11.2K ﹤0.01% 4971
2018
Q1 		$143K Buy
16,494
+6,944
+73% +$74.9K ﹤0.01% 5113
2017
Q4 		$119K Buy
9,550
+3,723
+64% +$42.7K ﹤0.01% 5110
2017
Q3 		$49K Buy
5,827
+5,201
+831% +$55K ﹤0.01% 5362
2017
Q2 		$10K Sell
626
-9,774
-94% -$194K ﹤0.01% 6068
2017
Q1 		$209K Buy
+10,400
New +$207K ﹤0.01% 4276
2016
Q3 		– Sell
-371
Closed -$3K – 6858
2016
Q2 		$3K Buy
+371
New +$3.1K ﹤0.01% 5882

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Barclays's ZYNE Position: Q4 2021 in Review

Barclays sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 7,268 shares — an estimated $31K sold.

Barclays first reported a position in ZYNE in Q2 2016 and held it in 20 quarters. The position peaked at $870K in Q2 2019. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

  • Barclays reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 7,268 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $31K.
  • Barclays first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 20 quarters.
  • Barclays's Zynerba Pharmaceuticals, Inc position peaked at $870K in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.